title: Proteomics in melanoma biomarker discovery: great potential, many obstacles.
abstract: The present clinical staging of melanoma stratifies patients into heterogeneous groups, resulting in the application of aggressive therapies to large populations, diluting impact and increasing toxicity. To move to a new era of therapeutic decisions based on highly specific tumor profiling, the discovery and validation of new prognostic and predictive biomarkers in melanoma is critical. Genomic profiling, which is showing promise in other solid tumors, requires fresh tissue from a large number of primary tumors, and thus faces a unique challenge in melanoma. For this and other reasons, proteomics appears to be an ideal choice for the discovery of new melanoma biomarkers. Several approaches to proteomics have been utilized in the search for clinically relevant biomarkers, but to date the results have been relatively limited. This article will review the present work using both tissue and serum proteomics in the search for melanoma biomarkers, highlighting both the relative advantages and disadvantages of each approach. In addition, we review several of the major obstacles that need to be overcome in order to advance the field.
authors.affiliation: Department of Surgery, University of Michigan Health Systems, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Sabel
authors.forename: Yashu
authors.initials: Y
authors.lastname: Liu
authors.forename: David M
authors.initials: DM
authors.lastname: Lubman
references.citation: J Proteome Res. 2007 Mar;6(3):1038-47
references.pmid: 17266348
references.citation: Trends Biotechnol. 2001 Oct;19(10 Suppl):S40-8
references.pmid: 11780970
references.citation: J Clin Oncol. 1999 Jun;17(6):1891-6
references.pmid: 10561230
references.citation: J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S9-S14
references.pmid: 18801142
references.citation: Electrophoresis. 1995 Jul;16(7):1087-9
references.pmid: 7498151
references.citation: Dermatology. 2005;210(1):39-44
references.pmid: 15604544
references.citation: Expert Rev Proteomics. 2008 Jun;5(3):405-12
references.pmid: 18532908
references.citation: Cancer Genomics Proteomics. 2010 Jan-Feb;7(1):17-23
references.pmid: 20181627
references.citation: N Engl J Med. 2004 Dec 30;351(27):2817-26
references.pmid: 15591335
references.citation: Clin Chem. 2003 Aug;49(8):1272-5
references.pmid: 12881441
references.citation: J Proteome Res. 2009 May;8(5):2501-10
references.pmid: 19222175
references.citation: Expert Rev Mol Diagn. 2010 Oct;10(7):897-919
references.pmid: 20964610
references.citation: Melanoma Res. 2005 Aug;15(4):235-44
references.pmid: 16034300
references.citation: J Natl Cancer Inst. 2004 Mar 3;96(5):353-6
references.pmid: 14996856
references.citation: Cancer Lett. 2009 Oct 8;283(2):222-9
references.pmid: 19394758
references.citation: J Cancer Res Clin Oncol. 2009 Sep;135(9):1257-64
references.pmid: 19288131
references.citation: Ann Oncol. 2009 Aug;20 Suppl 6:vi8-13
references.pmid: 19617299
references.citation: Anticancer Res. 1997 Nov-Dec;17(6D):4359-70
references.pmid: 9494534
references.citation: J Histochem Cytochem. 2006 Jun;54(6):739-43
references.pmid: 16399996
references.citation: Electrophoresis. 2003 Jul;24(14):2386-404
references.pmid: 12874874
references.citation: Oncogene. 2003 May 19;22(20):3180-7
references.pmid: 12789294
references.citation: Biochem Biophys Res Commun. 2002 Apr 5;292(3):587-92
references.pmid: 11922607
references.citation: J Proteomics. 2011 Jun 10;74(7):1002-14
references.pmid: 21549228
references.citation: Adv Immunol. 2006;90:215-41
references.pmid: 16730265
references.citation: Cancer Control. 2009 Jul;16(3):219-24
references.pmid: 19556961
references.citation: J Clin Oncol. 2005 Aug 1;23(22):5088-93
references.pmid: 16051955
references.citation: Oncogene. 2007 Jan 4;26(1):65-76
references.pmid: 16799640
references.citation: Ann Oncol. 2010 May;21 Suppl 5:v194-7
references.pmid: 20555080
references.citation: Mol Cell Proteomics. 2005 Nov;4(11):1741-53
references.pmid: 16091476
references.citation: FEBS J. 2009 Dec;276(23):6880-904
references.pmid: 19860826
references.citation: Electrophoresis. 1999 Apr-May;20(4-5):689-700
references.pmid: 10344234
references.citation: Nat Med. 2001 Apr;7(4):493-6
references.pmid: 11283679
references.citation: Clin Chem. 2002 Aug;48(8):1160-9
references.pmid: 12142368
references.citation: Pigment Cell Res. 2003 Jun;16(3):254-60
references.pmid: 12753398
references.citation: J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61
references.pmid: 11459866
references.citation: Arch Dermatol Res. 2007 Mar;298(10):469-77
references.pmid: 17221215
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6199-206
references.pmid: 19917835
references.citation: J Clin Oncol. 2009 May 1;27(13):2199-208
references.pmid: 19307507
references.citation: J Proteome Res. 2005 Nov-Dec;4(6):2404-11
references.pmid: 16335994
references.citation: Lancet Oncol. 2010 Jan;11(1):55-65
references.pmid: 20005174
references.citation: J Proteome Res. 2010 Jul 2;9(7):3656-63
references.pmid: 20459140
references.citation: J Proteome Res. 2010 Nov 5;9(11):6044-51
references.pmid: 20879797
references.citation: Cancer Res. 2003 Oct 15;63(20):6716-25
references.pmid: 14583466
references.citation: Ann N Y Acad Sci. 2004 Jun;1022:317-22
references.pmid: 15251977